A5020488064- Acute Myeloid Leukemia Research
- Cancer-related molecular mechanisms research
- RNA Research and Splicing
- Histone Deacetylase Inhibitors Research
- Circular RNAs in diseases
- Mycobacterium research and diagnosis
- RNA modifications and cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Telomeres, Telomerase, and Senescence
- Acute Lymphoblastic Leukemia research
- Molecular Biology Techniques and Applications
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Vascular Tumors and Angiosarcomas
Institute of Haematology and Blood Transfusion
2021-2024
Charles University
2021-2022
Institute for Transfusion Medicine
2022
Abstract Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive LR-MDS progression and uncover cellular pathways contributing malignant transformation. The mutational landscape was analyzed in 214 patients, at least one mutation detected 137 patients (64%). Mutated RUNX1 identified as the main predictor rapid by statistics machine...
Mutations in the splicing factor 3b subunit 1 ( SF3B1 ) gene are frequent myelodysplastic neoplasms (MDS). Because process is involved production of circular RNAs (circRNAs), we investigated impact mutations on circRNA processing. Using RNA sequencing, measured expression CD34+ bone marrow MDS cells. We defined circRNAs deregulated a heterogeneous group patients and described increased formation higher‐risk MDS. showed that presence did not affect global circRNAs; however, deregulation...
Abstract Patients with myelodysplastic neoplasms (MDS) are classified according to the risk of acute myeloid leukemia transformation. Some lower‐risk MDS patients (LR‐MDS) progress rapidly despite expected good prognosis. Using diagnostic samples, we aimed uncover mechanisms this accelerated progression at transcriptome level. RNAseq was performed on CD34+ ribodepleted RNA samples from 53 LR‐MDS without (stMDS) and 8 who progressed within 20 months (prMDS); 845 genes were differentially...
To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34+ hematopoietic stem/progenitor cells (HSPCs) isolated from 25 MDS/AML-MRC patients discovery cohort (10 AZA responders (RD), six stable disease, nine progressive disease (PD) during therapy) eight controls. Eleven samples were also available for...